Log in
NASDAQ:AVRO

AVROBIO Stock Forecast, Price & News

$13.27
-0.12 (-0.90 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.86
Now: $13.27
$13.53
50-Day Range
$13.39
MA: $15.20
$17.10
52-Week Range
$9.76
Now: $13.27
$29.32
Volume355,177 shs
Average Volume295,900 shs
Market Capitalization$483.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.89 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
CUSIPN/A
CIKN/A
Phone617-914-8420
Employees123

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.70 per share

Profitability

Net Income$-72,960,000.00

Miscellaneous

Market Cap$483.70 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
$13.27
-0.12 (-0.90 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AVROBIO (NASDAQ:AVRO) Frequently Asked Questions

How has AVROBIO's stock price been impacted by Coronavirus (COVID-19)?

AVROBIO's stock was trading at $18.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AVRO stock has decreased by 26.4% and is now trading at $13.27.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AVROBIO?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AVROBIO
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AVROBIO?

Wall Street analysts have given AVROBIO a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AVROBIO wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for AVROBIO
.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) released its quarterly earnings results on Tuesday, November, 10th. The company reported ($1.01) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.81) by $0.20.
View AVROBIO's earnings history
.

What price target have analysts set for AVRO?

7 analysts have issued 1-year price targets for AVROBIO's stock. Their forecasts range from $13.00 to $43.00. On average, they expect AVROBIO's stock price to reach $32.17 in the next year. This suggests a possible upside of 142.4% from the stock's current price.
View analysts' price targets for AVROBIO
.

Who are some of AVROBIO's key competitors?

What other stocks do shareholders of AVROBIO own?

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:
  • Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 54, Pay $746.7k)
  • Mr. Erik Ostrowski, CFO & Treasurer (Age 47, Pay $739.58k)
  • Mr. Steven N. Avruch J.D., Chief Legal Officer & Sec. (Age 59, Pay $441.68k)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Matthew Arnold, Head of Operations
  • Mr. Kim Raineri M.B.A., Chief Manufacturing & Technology Officer
  • Mr. Chris Mason, Chief Scientific Officer
  • Ms. Monique Da Silva, Sr. VP of Corp. Communications
  • Ms. Georgette Verdin, Chief HR Officer
  • Ms. Deanna M. Petersen, Chief Bus. Officer (Age 58)

When did AVROBIO IPO?

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by many different institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (9.97%), BlackRock Inc. (7.05%), Camber Capital Management LP (4.94%), State Street Corp (3.57%), Emerald Advisers LLC (2.21%) and Emerald Mutual Fund Advisers Trust (1.94%). Company insiders that own AVROBIO stock include Bruce Booth, Christopher Paige and Geoffrey Mackay.
View institutional ownership trends for AVROBIO
.

Which institutional investors are selling AVROBIO stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Vivo Capital LLC, Wells Fargo & Company MN, Emerald Mutual Fund Advisers Trust, Victory Capital Management Inc., Squarepoint Ops LLC, Emerald Advisers LLC, and Morgan Stanley. Company insiders that have sold AVROBIO company stock in the last year include Christopher Paige, and Geoffrey Mackay.
View insider buying and selling activity for AVROBIO
.

Which institutional investors are buying AVROBIO stock?

AVRO stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Camber Capital Management LP, Federated Hermes Inc., Sphera Funds Management LTD., State Street Corp, BlackRock Inc., Charles Schwab Investment Management Inc., and Boothbay Fund Management LLC.
View insider buying and selling activity for AVROBIO
.

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $13.27.

How big of a company is AVROBIO?

AVROBIO has a market capitalization of $483.70 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. AVROBIO employs 123 workers across the globe.

What is AVROBIO's official website?

The official website for AVROBIO is www.avrobio.com.

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.